NCT07613788尚未招募2 期
A Study to Evaluate the Efficacy and Safety of Rimegepant Plus Glofitamab and CD19 CAR-T Cell Therapy in Patients With High-Risk Relapsed/Refractory Large B-Cell Lymphoma
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 100
- 试验地点
- 1
研究概览
简要总结
This study is designed to evaluate the efficacy and safety of rimegepant in combination with glofitamab and CD19 CAR-T cell therapy in patients with high-risk relapsed/refractory large B-cell lymphoma. Eligible patients will be randomized to receive glofitamab plus CD19 CAR-T cell therapy with or without rimegepant. The primary endpoint is complete response rate at 6 months after CAR-T cell infusion.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Able to understand and voluntarily sign the written informed consent form.
- •Age 18 years or older.
- •Histologically confirmed large B-cell lymphoma with CD19 and CD20 expression.
- •Relapsed or refractory disease after at least one prior line of systemic therapy.
- •Prior treatment must have included an anthracycline-containing chemotherapy regimen and an anti-CD20 monoclonal antibody.
- •Considered suitable by the investigator to receive glofitamab and CD19 CAR-T cell therapy.
- •Presence of at least one high-risk feature, including extranodal involvement, bulky disease, or TP53 abnormality.
- •ECOG performance status of 0 to
- •Life expectancy of at least 12 weeks.
- •Adequate bone marrow, hepatic, renal, pulmonary, and cardiac function as determined by the investigator.
- •Participants of reproductive potential must agree to use effective contraception during the study period.
- •Able and willing to comply with the study protocol, in the investigator's judgment.
排除标准
- •History of hypersensitivity to any study treatment or related compounds.
- •Active or uncontrolled infection requiring systemic treatment.
- •History of allogeneic hematopoietic stem cell transplantation or organ transplantation.
- •Uncontrolled or clinically significant viral infection as defined by the protocol.
- •Known central nervous system involvement by lymphoma or clinically significant central nervous system disease that may interfere with study treatment or safety assessment.
- •Severe or uncontrolled cardiovascular disease.
- •Severe autoimmune disease or immune-mediated disease that may interfere with study treatment or safety assessment.
- •Known or suspected history of hemophagocytic lymphohistiocytosis.
- •Recent thromboembolic event before screening.
- •History of another malignancy within 5 years before screening, except adequately treated carcinoma in situ or non-melanoma skin cancer.
- •Receipt of prohibited anticancer therapy, immunosuppressive therapy, live attenuated vaccine, or other prohibited treatment within the protocol-specified period before enrollment.
- •Pregnant or breastfeeding women, or participants planning pregnancy during the study period.
- •Concurrent participation in another interventional clinical trial.
- •Need for prohibited concomitant medications that cannot be discontinued or substituted.
- •Any condition that, in the investigator's judgment, makes the participant unsuitable for study treatment or study participation.
研究者
Zhao Weili
Professor and Director, Shanghai Institute of Hematology
Ruijin Hospital
研究点 (1)
Loading locations...
相似试验
尚未招募
3 期
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual MigraineCTRI/2025/11/097643Pfizer Inc.470
招募中
3 期
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in adolescent SubjectsCTRI/2025/02/081278Pfizer Inc.200
尚未招募
1 期
Rimegepant Combined With AG Chemotherapy As First-Line Treatment For Metastatic Pancreatic Ductal AdenocarcinomaNCT07475234Xiuchao Wang30
尚未招募
1 期
Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell LymphomaNCT07444710National Cancer Institute (NCI)16
尚未招募
不适用
Real-World Effectiveness and Safety of Glofitamab in Primary Refractory and Early Relapsed Diffuse Large B-Cell LymphomaNCT07472621Henan Cancer Hospital20